



Contact:

Caroline Green
InnerOptic Technology, Inc
919/732.2090
caroline@inneroptic.com

FOR IMMEDIATE RELEASE

INNEROPTIC RECEIVES FUNDING

Hillsborough, NC (December 17, 2007) – InnerOptic Technology, Inc., provider of cutting-edge visualization products for minimally-invasive surgery (MIS), announces closing of two early round investments. A private “angel” investor, a member of the Triangle Accredited Capital Forum (TACF), has placed a \$100,000 investment in the company after thorough due diligence and based upon confidence in InnerOptic’s business plan, technology and management team. In this same pre-round, we have also signed with CatoBioventures for up to \$270,000 of equity investment along with signing a strategic development relationship with the Cato Research Ltd. to bring InnerOptic’s medical products through FDA certification.

InnerOptic Co-Founder and CTO Kurtis Keller commented, "We at InnerOptic are thrilled to receive these early investments. We are excited to be able to accelerate development of our technology, which we believe will dramatically improve minimally invasive surgery."

“Attracting private investment demonstrates a major vote of confidence in InnerOptic’s strategy. This funding will allow us to achieve several important product development milestones in the next few months,” said Brian Heaney, InnerOptic CEO.

“We are proud to have been able to introduce InnerOptic to the angel investor members of the Capital Forum. This company has unique technology and an attractive value proposition that will serve it well as it enters the market,” said Bill Warner, Chairman, Triangle Accredited Capital Forum.

InnerOptic will use these funds to accelerate the development and FDA approval of the InVision System products. InVision allows a surgeon to more easily use laparoscope

ultrasound during minimally-invasive surgical procedures. By using InVision, a surgery is easier and safer to perform, resulting in better patient outcomes.

About InnerOptic Technology, Inc

InnerOptic was founded in 2003 to commercialize the patented medical visualization technology developed by researchers at the University of North Carolina at Chapel Hill. A privately held company, InnerOptic is currently head-quartered in Hillsborough. For more information, please visit <http://www.inneroptic.com/>

About Cato BioVentures

Cato BioVentures is the venture capital affiliate of [Cato Research Ltd.](#), a leading contract research and development organization (CRO). For nearly 20 years, Cato BioVentures and Cato Research have assisted entrepreneurs and established management teams in building successful life science companies. We focus on early-stage investment opportunities in private companies and PIPE opportunities in undervalued public companies. Through strategic CRO service agreements with Cato Research, we invest our in-kind service capital (CRO Service Capital™) in innovative therapeutics, medical devices, diagnostics and platform tools and technologies for improved drug discovery and development. <http://www.catobioventures.com/>